SpringLeaf Therapeutics, a Boston, MA-based company that develops a technology designed to expand availability of biologic therapeutics by meeting specific patient needs and enabling self-administration, has held a $4m second closing of its Series B financing.
New investor Excel Venture Management has joined existing backers SR One, Flybridge Capital Partners, and North Bridge Venture Partners.
This brings the total amount raised by the company in the round to $19m.
In conjunction with the funding, Enrico Petrillo, M.D., Managing Director at Excel Venture Management, will join SpringLeaf’s board of directors as an observer.
Led by President and CEO Frank Bobe, Ph.D., SpringLeaf Therapeutics has developed technology is based on the convergence of materials science and medicine and is designed to enable and differentiate therapeutics.
Related news: 12/05/2011: SpringLeaf Therapeutics Closes $15M Series B Financing